We are live on ! Find out more
NRIX icon

Nurix Therapeutics

184 hedge funds and large institutions have $2.15B invested in Nurix Therapeutics in 2025 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 93 increasing their positions, 29 reducing their positions, and 28 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more funds holding in top 10

Funds holding in top 10: 1 → 4 (+3)

221% more repeat investments, than reductions

Existing positions increased: 93 | Existing positions reduced: 29

219% more capital inflows, than outflows

Capital inflows: $623M | Capital outflows: $195M

192% more call options, than puts

Call options by funds: $4.74M | Put options by funds: $1.63M

46% more first-time investments, than exits

New positions opened: 41 | Existing positions closed: 28

37.47% more ownership

Funds ownership: 110.89% → 148.36% (+37%)

6% more funds holding

Funds holding: 173 → 184 (+11)

Holders
184
Holders Change
+11
Holders Change %
+6.36%
% of All Funds
2.21%
Holding in Top 10
4
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+300%
% of All Funds
0.05%
New
41
Increased
93
Reduced
29
Closed
28
Calls
$4.74​M
Puts
$1.63​M
Net Calls
+$3.12​M
Net Calls Change
+$2.1​M

NRIX Hedge Fund Activity: Q4 2025 in Review

184 of the 8,316 institutional investors tracked by Wall St. Rank reported a position in Nurix Therapeutics (NRIX) for Q4 2025, worth a combined $2.15B — up 175% from $783M a quarter earlier.

Buyers outnumbered sellers: 41 funds opened new NRIX positions and 28 closed out — a net gain of 13 holders — while 93 added to existing stakes and 29 trimmed.

The largest buyer was General Atlantic, opening a new position worth an estimated $70.4M. The largest seller was Fidelity Investments, cutting an estimated $66.8M.

  • 184 institutional investors held Nurix Therapeutics (NRIX) as of Q4 2025, up from 173 in Q3 2025.
  • Funds reported $2.15B of Nurix Therapeutics stock for Q4 2025, up 175% quarter-over-quarter.
  • 41 funds opened new Nurix Therapeutics positions in Q4 2025 and 28 closed out, a net change of +13 holders.
  • The largest Nurix Therapeutics buyer in Q4 2025 was General Atlantic, an estimated $70.4M added.
  • The largest Nurix Therapeutics seller in Q4 2025 was Fidelity Investments, an estimated $66.8M sold.

Based on aggregated 13F filings for Q4 2025.